Therapeutics News and Research

RSS

Myeloid derived suppressor cells provide niche where cancer stem cells survive

The immune system is normally known for protecting the body from illness. But a subset of immune cells appear to be doing more harm than good.

6 Sep 2013

Research uncovers defective process in patients with autosomal dominant polycystic kidney disease

New research has uncovered a process that is defective in patients with autosomal dominant polycystic kidney disease, a common cause of kidney failure. The findings, which appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), point to a new potential strategy for preventing and treating the disease.

6 Sep 2013

Researchers translate new technology to better study behaviors and cellular function to fruit flies

A team of researchers led by Charles D. Nichols, PhD, Associate Professor of Pharmacology at LSU Health Sciences Center New Orleans, has successfully translated a new technology to better study behaviors and cellular function to fruit flies.

6 Sep 2013

Thrombogenics, Bicycle Collaborate On Drugs Targeting Eye Diseases

...

5 Sep 2013

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

Rigel Pharmaceuticals, Inc. today announced its plans to focus the Company's resources on the completion of three lead clinical programs. These efforts include commencing a Phase 3 clinical study of fostamatinib, an oral SYK inhibitor, in Immune Thrombocytopenic Purpura pending discussions with regulatory agencies.

5 Sep 2013

ThromboGenics, Bicycle to develop and commercialize novel drugs for ophthalmic diseases

ThromboGenics NV, a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that it has entered into a collaboration and license agreement with Bicycle Therapeutics to develop and commercialize novel drugs inhibiting a specific target for the treatment of ophthalmic diseases, such as diabetic macular edema.

5 Sep 2013

£13M partnership to accelerate cancer-focused drug discovery launched by Queen's and Almac Discovery

A new -13 million partnership to accelerate cancer-focused drug discovery in Northern Ireland has been launched by Enterprise Minister Arlene Foster MLA.

5 Sep 2013

Research findings raise hope for new heart therapies

Many people who survive a heart attack find themselves back in the hospital with a failing heart just years later. And the outcome often is unfavorable, owing to limited treatment options. But scientists at Temple University School of Medicine's Cardiovascular Research Center recently found hope in an unlikely source - stem cells in cortical, or compact, bone.

5 Sep 2013

Repligen Earns $1M Pfizer Milestone Payment

...

4 Sep 2013

Study looks for molecular changes in genome caused by multiple sclerosis

The National Institutes of Health (NIH) awarded Benaroya Research Institute at Virginia Mason (BRI) a $1.9 million grant to find marks in the human genome which can explain why some white blood cells cause damage to the spinal cord and brain in multiple sclerosis (MS).

4 Sep 2013

Proteins in blood predict women at risk of pre-eclampsia during first pregnancy

Researchers from The University of Manchester and Central Manchester University Hospitals NHS Trust have identified proteins in the blood that could be used to predict whether a woman in her first pregnancy is at increased risk of developing pre-eclampsia.

From The University of Manchester 4 Sep 2013

Study: Changes in expression of various isoforms might play role in cancer development

Spool-like proteins called histones play a crucial role in packaging the nearly seven feet of DNA found in most human cells. A new study shows that a group of histones that are thought to behave the same way actually are functionally distinct proteins.

4 Sep 2013

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced positive top-line results from a Phase 2a study of ETC-1002 when added to statin therapy in patients with elevated levels of low density lipoprotein cholesterol (LDL-C or "bad cholesterol").

4 Sep 2013

Research shows how mucosal surfaces in body respond to C. albicans to prevent damage

Candida albicans is a common fungus found living in, and on, many parts of the human body. Usually this species causes no harm to humans unless it can breach the body's immune defences, where can lead to serious illness or death.

3 Sep 2013

Proteins in blood could predict woman at increased risk of developing pre-eclampsia

3 Sep 2013

Argininosuccinic aciduria (ASA) and gene therapy: an interview with Dr Julien Baruteau, UCL Institute for Women's Health, London

This rare genetic condition can theoretically affect patients at any age but symptoms are more often observed in childhood and even uncommonly during the first days of life.

2 Sep 2013

Roche's Herceptin formulation wins EU approval for treatment of HER2-positive breast cancer

Halozyme Therapeutics, Inc. announced today that the European Commission has granted Roche European Union marketing authorization for the use of a time-saving subcutaneous formulation of Herceptin (trastuzumab) for the treatment of HER2-positive breast cancer.

2 Sep 2013

Holistic approach to understand and treat TB

For years, physicians around the world have watched as strain after strain of the deadly bacteria Mycobacterium tuberculosis evolves resistance to drugs.

2 Sep 2013

Findings could alter ways in which doctors use platelets to treat traumatic injuries

A new finding could lead to novel treatments to reduce bleeding in trauma and severe infections.

2 Sep 2013

Researchers identify potential drug target to recover from jet lag, disruptions in circadian system

University of Notre Dame researchers, as part of a collaborative effort, have identified a protein that potentially could be a target for drugs that would help people recover faster from jet lag and better adjust their circadian rhythms during rotational shift work.

31 Aug 2013

Therapeutics News and Research

Myeloid derived suppressor cells provide niche where cancer stem cells survive

Research uncovers defective process in patients with autosomal dominant polycystic kidney disease

Researchers translate new technology to better study behaviors and cellular function to fruit flies

Thrombogenics, Bicycle Collaborate On Drugs Targeting Eye Diseases

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

ThromboGenics, Bicycle to develop and commercialize novel drugs for ophthalmic diseases

£13M partnership to accelerate cancer-focused drug discovery launched by Queen's and Almac Discovery

Research findings raise hope for new heart therapies

Repligen Earns $1M Pfizer Milestone Payment

Study looks for molecular changes in genome caused by multiple sclerosis

Proteins in blood predict women at risk of pre-eclampsia during first pregnancy

Study: Changes in expression of various isoforms might play role in cancer development

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Research shows how mucosal surfaces in body respond to C. albicans to prevent damage

Proteins in blood could predict woman at increased risk of developing pre-eclampsia

Argininosuccinic aciduria (ASA) and gene therapy: an interview with Dr Julien Baruteau, UCL Institute for Women's Health, London

Roche's Herceptin formulation wins EU approval for treatment of HER2-positive breast cancer

Holistic approach to understand and treat TB

Findings could alter ways in which doctors use platelets to treat traumatic injuries

Researchers identify potential drug target to recover from jet lag, disruptions in circadian system

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News